CENTERVILLE, MA--(Marketwire - June 16, 2010) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is pleased to announce that the Company’s UV-400 units have been in operation at two major Boston Hospitals, New England Baptist Hospital, and with the Division of Infectious Diseases at Massachusetts General Hospital, since April, with ongoing favorable responses and excellent feedback.
New England Baptist Hospital (NEBH) is an adult care medical/surgical hospital specializing in orthopedic care and complex orthopedic procedures. NEBH is an international leader in the treatment of all forms of musculoskeletal disorders and disease. Massachusetts General Hospital (Mass General or MGH) is a teaching hospital of Harvard Medical School and a biomedical research facility. It is ranked as one of the top five hospitals in the United States.
“These are two of the finest medical institutions in the world today,” said Bill Fegley, President of Puravair, the distributor responsible for the introduction of the ViraTech UV-400 to the Boston medical market. He further stated, “Hospitals generally look for ways to stay ahead of the curve regarding the safety of their patients and staff. These two particular hospitals are well known for their proactive approach in this area. Given the UV-400’s FDA clearance rating and lab test results which prove the unit kills over 99% of bacteria with every pass, how could any hospital not want to evaluate these units? We are thrilled with the feedback we’re getting from both hospitals, both of which have stated that the hospital staff is noticing less coughing and respiratory symptoms within the first week of operation of the ViraTech units.”
The Company plans to announce delivery and commercial availability of the newly updated product shortly. Those interested in the product, or wishing to pre-order are invited to contact the distributor, Puravair LLC, at 1-866-6-PURAVAIR or by email at info@puravair.com.
Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of biotechnology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
Email Contact
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
